Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2

被引：5
|
作者：
Armstrong, A. [1 ]
Eyerich, K. [2 ]
Conrad, C. [3 ]
Zhu, Y. [4 ]
Yang, Y. -w. [5 ]
Miller, M. [4 ]
You, Y. [4 ]
Shen, Y. -k. [4 ]
Foley, P. [6 ]
Griffiths, C. E. M. [7 ,8 ]
Strober, B. [9 ,10 ,11 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[2] Univ Freiburg, Baden Wurttemberg, Germany
[3] Lausanne Univ Hosp CHUV, Lausanne, Switzerland
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[6] Univ Melbourne, St Vincents Hosp Melbourne & Prob Med Res, Skin Hlth Inst, Carlton, Vic, Australia
[7] Univ Manchester, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Manchester, England
[8] Kings Coll London, Kings Coll Hosp, London, England
[9] Yale Univ, New Haven, CT USA
[10] Cent Connecticut Dermatol Res, Cromwell, CT USA
[11] Cent Connecticut Dermatol Res, 1 Willowbrook Rd, Cromwell, CT 06416 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 12期
关键词：
PHASE-III; THERAPY;
D O I：
10.1111/jdv.19309
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E1375 / E1379
页数：5
相关论文
共 50 条
  • [21] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
    Blauvelt, A.
    Papp, K.
    Griffiths, C. E. M.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y.
    Li, S.
    Kimball, A. B.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 40 - 40
  • [22] Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
    Papp, K. A.
    Blauvelt, A.
    Kimball, A. B.
    Han, C.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y. -K.
    Li, S.
    Griffiths, C. E. M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1515 - 1522
  • [23] Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    McElligott, Sean
    Muser, Erik
    Li, Nan
    Armstrong, April W.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (06) : 617 - 623
  • [24] Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: Results from the phase 3 VOYAGE 2 study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [25] Safety of guselkumab in patients with plaque psoriasis through 2 years: a pooled analysis from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Papp, K.
    Armstrong, A. W.
    Wasfi, Y.
    Jiang, G.
    Shen, Y-K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E297 - E297
  • [26] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    Armstrong, April W.
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Papp, Kim A.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) : 155 - 164
  • [27] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    April W. Armstrong
    Kristian Reich
    Peter Foley
    Chenglong Han
    Michael Song
    Yaung-Kaung Shen
    Yin You
    Kim A. Papp
    [J]. American Journal of Clinical Dermatology, 2019, 20 : 155 - 164
  • [28] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
  • [29] Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
    Reich, Kristian
    Strober, Bruce
    Langley, Richard
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Foley, Peter
    Blauvelt, Andrew
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [30] COMPARING EFFICACY OF GUSELKUMAB VERSUS USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS : AN ADJUSTED COMPARISON BASED ON VOYAGE 1&2 AND NAVIGATE TRIALS
    Diels, J.
    Thilakarathne, P.
    Schubert, A.
    McElligott, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A544 - A545
12345